Harrow Inc.
(NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children.
The eye care company said the move reflects its continued focus on underserved ophthalmic diseases and marks progress in executing its portfolio strategy.
Mark Baum, chief executive officer of Harrow, noted that VERKAZIA is the second of three priority products identified in the company's recent Letter to Stockholders that Harrow is actively advancing within its portfolio.
Read Also: Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst How Verkazia Works In VKC Treatment VERKAZIA is a topical calcineurin inhibitor immunomodulator designed to address the underlying inflammation associated with VKC.
